Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aids : Effectiveness of antiretroviral therapy demonstrated in Africa

28.06.2002


Tritherapies using antiretroviral drugs have proved their worth in industrialized countries in the fight against Aids. However, in Sub-Saharan Africa, where 70 % of people infected with HIV live, access to such treatments is extremely limited. High cost, complicated procedures, combined with inadequate infrastructures for following up patients or capable of delivering medicines regularly partly explain this situation. Moreover, efficacy of antiretroviral agents might not be the same for some HIV strains present in Africa. And not enough is yet known about the response to therapy (viral resistance, adverse effects and so on), notably in patients in advanced stages of immune deficiency. These factors are considered as obstacles to mounting concerted therapy programmes in Africa. For some government authorities they provide the arguments for concentrating control campaigns solely on prevention with no involvement of antiretroviral drugs.



Since 1998 the Senegalese government has been developing a programme facilitating access to Aids treatments (1). Within this, an assessment programme, coordinated by the IRD and the Senegal National Committee for Aids Control, and financed by the Agence nationale de recherches sur le sida (ANRS), has been deployed aiming to determine the effectiveness, the tolerance, the acceptability and feasibility of the standard form of antiretroviral therapy. This study was conducted in a cohort of 58 patients aged between 16 and 56 years, having high viral load and low CD4 cell count. Most of them (86.2%) had developed the disease before the start of the antiretroviral therapy. All received a combination treatment of two nucleoside reverse transcriptase inhibitors plus one protease inhibitor (2) The drugs were taken in three doses per day, just as in the industrialized countries. A sociological survey was done in parallel which assessed patients’ ability to contribute to part of the cost of the treatment depending on their financial resources. The rest would be subsidized by the programme.

At the end of the 18 month study, the results were comparable with those obtained in the countries of the North. Most patients (87.9 %) regularly followed the course of treatment over the whole period monitored. Also, contrary to prior assumptions, financial difficulties did not hinder adherence to the therapy. Furthermore, the same therapeutic efficacy was observed here as in the industrialized countries. After a year and a half of treatment the viral load was almost undetectable (below 500 copies/ml) in 59.3 % of cases and the CD4 cell count had risen markedly (about 180/mm3). Tolerance to antiretroviral medicines was generally good, adverse effects observed being only mild. Only two cases of viral resistance to the drugs were found.


This study gives proof that the therapeutic strategies developed in the industrialized countries can also be applied in Africa. The Senegalese initiative shows that this tritherapy method proves to be effective for most patients, even if their immunity deficiency is severe before embarking on antiretroviral treatments - and although many different strains of HIV-1 are circulating. It must be emphasized also that, contrary to results of several other studies conducted in Africa, viral resistance was rare. The researchers consider that the quality of follow-up of patients under the therapy regimens, attained by involving social workers and the regularity of medicine supply, contributed to the effectiveness. Judging by the excellent results obtained during this pilot phase, it now remains to ascertain that antiretroviral therapy maintains its efficacy over the long term and on a larger scale.

(1) Senegal, which launched its HAART in 1998, was among the first African countries, along with the Ivory Coast and Uganda, to set up a nation-wide programme to facilitate access to treatment for Aids.

(2) These antiretroviral drugs are active against two HIV targets : reverse transcriptase and protease. Both are enzymes. The first enables the viral RNA to transform into DNA so it can then become integrated with the DNA of the cell it infects. Protease builds up the constituent elements of the HIV, before it is released from the cell to spread further.


Marie-Lise Sabrie | alfa

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>